Crossmark

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1136/jitc-2021-002485

Published Online: 2021-05-07

Published Print: 2021-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Leidner, Rom https://orcid.org/0000-0003-0788-7938
Crittenden, Marka

Young, Kristina

Xiao, Hong

Wu, Yaping

Couey, Marcus A

Patel, Ashish A

Cheng, Allen C

Watters, Amber L

Bifulco, Carlo

Morris, George

Rushforth, Lessli

Nemeth, Shorin

Urba, Walter J

Gough, Michael https://orcid.org/0000-0002-5575-0074
Bell, R Bryan https://orcid.org/0000-0002-3775-109X
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03247712 at ClinicalTrials.gov

Documents that mention this clinical trial

884 Tumor-directed immunoradiotherapy enhances surveillance from the sentinel lymph node
https://doi.org/10.1136/jitc-2023-sitc2023.0884

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2021-002485
Funding

Funding for this research was provided by:

Providence Portland Medical Foundation (N/A)

National Institutes of Health (R01 CA182311)

National Institutes of Health (R01 CA208644)

National Institutes of Health (R01 CA244142)
License Information

License valid from 2021-05-07

Document is current

Any future updates will be listed below